CURRICULUM VITAE

NAOKY CHIH-SU TSAI, MD

Castle Medical Center The Queen’s Medical Center 640 Ulukahiki St., Outpatient Clinic Liver Center/Liver Transplant Center Kailua, HI 96734 Queen’s POB 3 Phone: (808) 263-5174 550 S. Beretania St, Suite 405 Fax: (808) 266-3614 Phone: 808-691-8838 Fax: 808-691-8839 ______Update: 8/10/2019

MEDICAL SCHOOL Taipei Medical University Taipei, Taiwan, 1967-1974

POSTGRADUATE Internship in Internal Medicine Yale University Affiliated Residency Program St. Mary’s Hospital Waterbury, Connecticut July 1976-June1977

Residency in Internal Medicine Yale University Affiliated Residency Program The Griffin Hospital Derby, Connecticut July 1977-June 1979

Fellowship, G.I. State University of New York (SUNY) Buffalo, New York Buffalo General Hospital June 1979-July 1981

POSITIONS HELD Clinical Assistant Instructor of Medicine State University of New York at Buffalo School of Medicine, Buffalo, New York July 1979-June 1981

Chairman, Department of Medicine Castle Medical Center Kaneohe, HI 1984-1985

Clinical Assistant Professor of Medicine John A. Burns School of Medicine University of Hawaii Honolulu, Hawaii July 1987-June 1992

Member Trustee Board Castle Medical Center Kaneohe, Hawaii 1992-September 1, 1996

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 1 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017

Assistant Clinical Professor of Medicine John A. Burns School of Medicine University of Hawaii Honolulu, Hawaii July 1992-August 1996

Medical Director, Liver Transplant Program St. Francis Medical Center Honolulu, Hawaii November 1992 - January, 2007

Medical Director, Liver Transplant Program Hawaii Medical Center East Honolulu, Hawaii January, 2007 – December,2011

Medical Director, Liver Center St. Francis Medical Center Honolulu, Hawaii February 8, 1995 - January, 2007

Medical Director, Liver Center Hawaii Medical Center Honolulu, Hawaii January, 2007 – December 2011

Medical Director, Liver Center/ Liver Transplant program Queens Medical Center Honolulu, Hawaii Jan.2012-June 30 2017

Associate Professor of Medicine Chief, Section of Hepatobiliary Disease Division of Gastroenterology Department of Medicine John A. Burns School of Medicine University of Hawaii September 1996- July 31, 2003

Professor of Medicine Department of Medicine John A. Burns School of Medicine University of Hawaii July 31, 2003-June 30th 2013

Clinical Professor of Medicine Department of Medicine John A. Burns School of Medicine University of Hawaii June 16th, 2013 – present

Medical Director Queens Liver Transplant Program Queens Medical Center Honolulu Hawaii

Member, Steering Committee U.S. – Japan Autoimmune Liver Disease Association

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 2 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Member Abstract Review Group for American Association for the Study of Liver Disease (AASLD) 2001-2003, 2010-2012

UNOS certified Transplant Hepatologist, Feb. 2002

Appointed Member Editorial Board Hepatitis B Watch (HBV Watch), December 6, 2002.

Co-moderator: Clinical Forum Management of Chronic Hepatitis B AASLD/DDW May 2010

Guest Editor: Clinics in Liver Disease Aug. 2010

AASLD Abstracts Reviewer- 2010-2012

POST GRADUATE Educational Council for Foreign Medical Graduates (ECFMG) EXAMINATIONS January 1974, 3 214 066 3

Federal Licensure Examination (FLEX) June 1977

Diplomate American Board of Internal Medicine (ABIM) September 1979

Diplomate ABIM for Gastroenterology, November 1981

LICENSURE Taipei, Taiwan, Republic of China, 1974 Massachusetts State License #41704, September 1977 (inactive) Hawaii State License, #3796, February 1980

HOSPITAL AFFILIATIOINS The Queen’s Medical Center 1301 Punchbowl Street Honolulu, HI 96813 December, 2011 – present

Castle Medical Center 640 ‘Ulukahiki Kailua, HI 96734 August, 1981 - present

Hawaii Medical Center 2230 Liliha Street Honolulu, HI 96817 January, 2007 – December, 2011

St. Francis Medical Center 2230 Liliha Street Honolulu, HI 96817 November, 1992 – December, 2006

MEMBERSHIPS Member, American Gastroenterological Association (AGA) Member, American Association for Study of Liver Diseases (AASLD) Member, Scientific Committee, U.S. – Japan Association for Autoimmune Liver Disease Member, Scientific Advisory Panel – American Gastroenterological Association Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 3 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Member, European Association for Study of Liver (EASL)

Journal Article Review Hepatology, J. Hepatology, J. Clinical Hepatology and Gastroenterology J. Clinical Infectious Disease, J. Medical Virology, Journal of Clinical Gastroenterology .Gastroenterology.

NIH Grant:

UO1 DK082863 (F021481) Chronic Hepatitis B Clinical Research Network from November 1st 2008 to June 2017 : P.I. Naoky Tsai MD

PUBLICATIONS:

Changing demographics among populations prescribed HCV treatment, 2013-2017. Tsai N, Bacon B, Curry M, Flamm SL, Milligan S, Wick N, Younossi Z, Afdhal N. Am J Manag Care. 2019 Jul;25(7):319-323. PMID:31318504 Free Article Similar articles

Select item 31082876 4. Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N; Hepatitis B Research Network (HBRN). Am J Gastroenterol. 2019 Aug;114(8):1283-1291. doi: 10.14309/ajg.0000000000000221. PMID:31082876

Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print] PMID:31173468 Similar articles Select item 31108015 Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators. J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13132. [Epub ahead of print] PMID:31108015 Similar articles Select item 31082876 Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N; Hepatitis B Research Network (HBRN). Am J Gastroenterol. 2019 May 1. doi: 10.14309/ajg.0000000000000221. [Epub ahead of print] PMID:31082876 Similar articles Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 4 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017

Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection. Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network (HBRN). Hepatology. 2018 Dec 14. doi: 10.1002/hep.30417. [Epub ahead of print] PMID:30549279

Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN). Diabetes Care. 2018 Mar 29. pii: dc180040. doi: 10.2337/dc18-0040. [Epub ahead of print] PMID:29599296

Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes. Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Younossi I, Racila A. Clin Gastroenterol Hepatol. 2018 Mar 2. pii: S1542-3565(18)30225-8. doi: 10.1016/j.cgh.2018.02.037. [Epub ahead of print] PMID:29505905

PET/CT with 18F Fluorocholine as an Imaging Biomarker for Chronic Liver Disease: A Preliminary Radiopathologic Correspondence Study in Patients with Liver Cancer. Kwee SA, Wong L, Chan OTM, Kalathil S, Tsai N. Radiology. 2018 Jan 9:171333. doi: 10.1148/radiol.2018171333. [Epub ahead of print] PMID: 29315063

Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B. Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408-X. doi: 10.1016/j.jhep.2017.10.027. [Epub ahead of print] PMID:28706177

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, Ghany MG; Hepatitis B Research Network (HBRN). J Viral Hepat. 2017 Nov;24(11):1032-1042. doi: 10.1111/jvh.12732. Epub 2017 Jul 3. PMID:28581155

Select item 28027579 4. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P. Hepatology. 2017 Apr;65(4):1094-1103. doi: 10.1002/hep.29005. Epub 2017 Feb 25. Review. PMID:28027579

Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Clin Mol Hepatol. 2017 Jul 14. doi: 10.3350/cmh.2017.0008. [Epub ahead of print]

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 5 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 PMID:28706177 Free Article Similar articles

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. J Viral Hepat. 2017 Jan;24(1):22-27. doi: 10.1111/jvh.12611. PMID: 27730717

Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes with Ledipasvir and Sofosbuvir in a Real-World Cohort Study. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH. Hepatology. 2016 Aug 17. doi: 10.1002/hep.28782. PMID: 27533287

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. Gane E, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34834-X. doi: 10.1053/j.gastro.2016.07.038. PMID: 27486033

Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. Song MA, Kwee SA, Tiirikainen M, Hernandez BY, Okimoto G, Tsai NC, Wong LL, Yu H. Epigenetics. 2016 Jun 2;11(6):464-74. doi: 10.1080/15592294.2016.1151586. Epub 2016 Jun 1. PMID: 27248055

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. Younossi ZM, Bacon BR, Dieterich DT, Flamm SL, Kowdley K, Milligan S, Tsai N, Nezam A. J Viral Hepat. 2016 Jun;23(6):447-54. doi: 10.1111/jvh.12506. PMID: 26840452

Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Roytman M, Ramkissoon R, Wu C, Hong L, Trujillo R, Huddleston L, Poerzgen P, Seto T, Wong L, Tsai N. Hepatol Int. 2016 Mar 30. [Epub ahead of print] PMID: 27026431

Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response. Wu CJ, Roytman MM, Hong LK, Huddleston L, Trujillo R, Cheung A, Poerzgen P, Tsai NC. Hawaii J Med Public Health. 2015 Sep;74(9 Suppl 2):3-7. PMID: 26793407

Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM; Hepatitis B Research Network. Gastroenterology. 2016 Mar;150(3):684-695.e5. doi: 10.1053/j.gastro.2015.11.050. Epub 2015 Dec 10. PMID: 26684441

Hepatology. 2015 Aug 8. doi: 10.1002/hep.28110. [Epub ahead of print] Diabetes and prediabetes in patients with hepatitis B residing in North America.

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 6 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Khalili M1, Lombardero M2, Chung RT3, Terrault NA1, Ghany MG4, Kim WR5, Lau D6, Lisker-Melman M7, Sanyal A8, Lok AS9; HBRN. Collaborators (33) Roberts LR, Smith CI, Di Bisceglie AM, Brunt EM, Janssen HL, Wong DK, Juan J, Feld J, Yim C, Heathcote J, Lee WM, Perrillo R, Do S, Han SB, Tran TT, Cooper SL, Fontana RJ, Tsai N, Fried MW, Patel K, Evon D, Carithers RC, Shuhart M, Kowdley KV, Wang CC, Sterling RK, Liang TJ, Chang KM, Park JJ, Belle S, Wahed A, Cloonan Y, Kleiner D.

Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response Hawaii J Med Public Health. 2015 Aug;74 (9):3-7. Christin a J. Wu BS; Marina M. Roytman MD; Leena K. Hong PA-C; Leslie Huddleston PA-C, RN; Ruby Trujillo APRN; Alvin Cheung; Peter Poerzgen PhD; and Naoky C.S. Tsai MD

Autoimmune Hepatitis in Hawai'i. Kim TI, Kagihara JE, Tsai NC, Roytman MM. Hawaii J Med Public Health. 2015 Aug;74(8):270-4. PMID: 26279964

Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [18F]fluorocholine PET/CT. Kwee SA, Wong LL, Hernandez BY, Chan OT, Sato MM, Tsai N. Diagnostics (Basel). 2015;5(2):189-199. PMID:26090216

Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.

Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, Wantuck J, Roytman MM, Tsai N, Cheung R, Li J, Nguyen MH. Dig Dis Sci. 2015 Mar 28. [Epub ahead of print] PMID: 25821099

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection.

Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Mani Subramanian G, Gane E, Marcellin P. Dig Dis Sci. 2014 Dec 23. [Epub ahead of print] PMID: 25532501

The changing characteristics of hepatocellular cancer in Hawaii over time.

Wong LL, Ogihara M, Ji J, Tsai N. Am J Surg. 2014 Oct 13. pii: S0002-9610(14)00502-9. doi: 10.1016/j.amjsurg.2014.06.036. [Epub ahead of print] PMID: 25510478

Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Dig Dis Sci. 2015 Jan;60(1):260-8. doi: 10.1007/s10620-014- 3336-7. Epub 2014 Sep 2. PMID: 25179493

Outbreak of Severe Hepatitis Linked to Weight-Loss Supplement OxyELITE Pro. Roytman MM, Pörzgen P, Lee CL, Huddleston L, Kuo TT, Bryant-Greenwood P, Wong LL, Tsai N. Am J Gastroenterol. 2014 Aug;109(8):1296-8. doi: 10.1038/ajg.2014.159. PMID: 25091255 [PubMed - in process]

Use of Tenofovir Disoproxil Fumarate in Highly Viremic, Hepatitis B Mono-Infected Pregnant Women. Tsai PJ, Chang A, Yamada S, Tsai N, Bartholomew ML. Dig Dis Sci. 2014 Jun 5. [Epub ahead of print]

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 7 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 PMID:24898100

Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Uribe LA, O'Brien CG, Wong RJ, Gish RR, Tsai N, Nguyen MH. J Clin Gastroenterol. 2014 May 22. [Epub ahead of print] PMID:24859715

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. PMID: 24795200 Trial and error investigational drug induced liver injury, a case series report. Marumoto A, Roytman MM, Tsai NC. Hawaii J Med Public Health, 2013 Sep; 72 (9 Suppl 4):30-3 [PMID: 24052916]

New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Akiyama MJ, Piotrowski JI, Roytman MM, Chan SM, Hong LK, Huddleston, L, Trujillo R, Tsai NC. Hawaii J Med Public Health. 2013 Sep; 72 (9 Suppl 4):6-13. [PMID: 24052911]

Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Hernandez BY, Zhu X, Kwee SA, Chan O, Tsai N, Okimoto G, Horio D, McGlynn KA, Altedruse SF, Wong LL. Cancer Epidermiol Biomarkers Prev. 2013 Aug 27. [Epub ahead of print] PMID:23983238

JUMP-C: A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology. 2013 Jan 28. doi: 10.1002/hep.26275. [Epub ahead of print Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Munson ML, Chen YC, Najera I, Thommes J; on behalf of the JUMP-C Investigators

“Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.” Pan CQ, Hu KQ, Tsai N. Antivir Ther. 2012 Nov 23. PMID:23178555

“Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective.” Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T. Clinicoecon Outcomes Res. 2012;4:227-35. Epub 2012 Aug 23. PMID:22977309

“Brief Communications: High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients with Hepatitis B e Antigen-Postiive Chronic Hepatitis B”, Calvin Q. Pan, Myron Tong, Kris V. Kowdley, Ke-Qin Hu, Ting-Tsung Chang, Ching-Lung Lai, Seung Kew Yoon, Samuel S. Lee, David Cohen, Hong Tang, and, Naoky Tsai. Clinical Gastroenterology and Hepatology, 2012:10, 1047-1050.

“Cost-Effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective”. Naoky Tsai, Lennox Jeffers, Lael Cragin, Sonja Sorensen, Wenqing Su, Lisa Rosenblatt, Hong Tang, Tony Hebden, Timothy Juday. ClinicoEconomics and Outcomes Research 2012:4, 227-235.

“Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901”. Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Expert Opin Drug Saf. 2012 Jan 11. [Epub ahead of print] PMID: 22233350

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 8 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 "Healthcare disparities in Asians and Pacific Islanders with hepatocellular cancer". Wong LL, Hernandez B, Kwee S, Albright CL, Okimoto G, Tsai N. Am J Surg. 2012 Jan 6. [Epub ahead of print] PMID: 22227170

"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with decompensation: A randomized, open-label study"† Hepatology July 2011 54:91-100. Yun-Fan Liaw1,*,‡, Maria Raptopoulou-Gigi2, Hugo Cheinquer3,Shiv Kumar Sarin4, Tawesak Tanwandee5, Nancy Leung6, Cheng-Yuan Peng7, Robert P. Myers8, Robert S. Brown Jr9, Lennox Jeffers10, Naoky Tsai11, Jolanta Bialkowska12, Shijie Tang13, Suzanne Beebe13, Elizabeth Cooney13

“Chronic Hepatitis B: An Update” Guest Editor Naoky Tsai. Clinics in Liver Disease Aug. 2010.Volume 14.Number 3

“Hydroxycut ( Herbal Weight Loss Supplement ) Induced Hepatotoxicity: A Case Report and Review of Literature”. T. Sharma, L.Wong, N.Tsai, and R. Wong. Aug. 2010 Hawaii Medical Journal 69, no.8 p188-190

“Entecavir Treatment for up to 5 years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B”. Ting-Tsung Chang, Ching-Lung Lai, Seungkew Yoon, Samuel S. Lee, Henrique Sergio M. Coelho, Flair Jose Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, NaokyTsai, Hui Zhang, Daniel J. Tenny, Ricardo Tamez, and Uchenna Iloeje. Hepatology Feb. 2010 51:422-430

“Liver Transplant Referrals: The Burden of End Stage Liver Disease in Hawaii” Linda Wong, Naoky Tsai, Tarun Sharma, Makoto Ogihara, Chet Hammill, Jane Lee. Hawaii Medical Journal August 2009 Supple 1 Volune 68 #7 p.18-22

“Cholangiocarcinoma in Asian-Americans”, C. Hammill, J. Concepcion, L. Wong, and Naoky Tsai November 2008, Asian Pacific Journal of Clinical Oncology

“Seroepidemiology of Hepatitis B Virus Infection: Analysis of Mass Screening in Hawaii” Naoky Tsai, Aldrich Ricarte, Peter Holck, Linda Wong Hepatology International December 2008

“Entecavir Therapy for Lamivudine-Refractory Chronic Hepatitis B: Improved Virologic, Biochemical, and Serology Outcomes Through 96 Weeks”, M. Sherman, C.Yurdaydin, H. Simsek, M. Silva, YF Liaw, V.K. Rustgi, H. Sette, Naoky Tsai, D.J. Tenney, J. Vaughan, B. Kreter, R. Hindes, Hepatology, July 2008, v.48, No.1.

“Hepatocellular Carcinoma in Filipinos”, Linda L. Wong and Naoky Tsai, Asia-Pacific Journal of Clinical Oncology, 2007, V. 3, p. 84-88.

“The Additive Effects of Hepatitis C Infection and End-Stage Renal Disease in Porphyria Cutanea Tarda”, Owen T.M. Chan, Naoky Tsai, Ramona L. Wong, Allan K. Izumi, Cutis, December 2006, V. 78, No. 6, p. 397-400.

“Diagnosis and Management of Chronic Hepatitis B in the Primary Care Setting”, Naoky Tsai, Postgraduate Medicine, July-August 2006, p. 28-36.

“Liver Transplant in Hawaii: Over a Hundred Cases”, L. Wong, W.M. Limm, A. HS Cheung, H. Noguchi, Naoky Tsai, Hawai’i Medical Journal, Vol. 65, June 2006, p. 162-178.

“Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy”, Robert Perrillo, Robert Gish, Marion Peters, Emmet Keefe, Afredo Alberti, Maria Buti, W. Graham Cooksley, Michael Fried, Stephanos Hadziyannis, Yun-Fan Liaw, Nikolai Naoumov, Eugene Schiff, Chloe Thio, Naoky Tsai and Solko Schalm, Clinical Gastroenterology and Hepatology, 2006;4:233-248.

“Chronic Hepatitis B- From Prevention to Treatment” An Educational Monogram for Physicians, Brian J. McMahon, Naoky Tsai, Susan Wang, October 1,2005

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 9 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 “Management of Chronic Hepatitis B in Asian Americans and Pacific Islanders” N Tsai Gastroenterolgy and Hepatology, October 2005 1;3:188-194

“Hepatitis B and Alcohol affect survival of hepatocellular carcinoma patients” Linda Wong, Whitney Limm, Naoky Tsai, Richard Severino World Journal of Gastroenterology June 21, 2005; 11(23): 3491-97

Article Reviews for: “Outcome of Liver Transplantation for Hepatitis B in the United States,” “Peginterferon Alha-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HbeAg-Negative Chronic Hepatitis B,” and “A Phase II Dose-Escalating Trial of Clevudine in Patients with Chronic Hepatitis B,” Hepatitis Index & Reviews, Vol. 2(4). December 2004: pp.9-10

“Differences in Hepatitis C Virus Core Protein Processing Among Genotype 1 and 2” Takanobu Kato, Michiko Miyamoto, Tomoko Date, Akihiro Furusaka, Jun Hiramoto, Kazuo Nagayama, Naoky Tsai, Masashi Mizokami, Takaji Wakita; Hepatology Research 30; October 2004: pp. 204-209

“Practical Management of Chronic Hepatitis B” Naoky Tsai,M.D. in “ HBV Viral Kinetics and Clinical Management: Key Issues and Current Perspectives; Editor in Chief, Paul D. Berk, M.D.,Guest Editors, Emmet B. Keeffe M.D., and Jules L. Dienstag, M.D.” Seminars in Liver Disease, Vol. 24, suppl. 1, 2004 pp.71-76

“Genotyping and phylogenetic characterization of hepatitis B virus among multi-ethnic cohort in Hawaii” Mayumi Sakurai, Fuminaka Sugauchi, Naoky Tsai, Seiji Suzuki, Izumi Hasegawa, Kei Fujiwara, Etsuro Orito, Ryuzo Ueda, Masashi Mizokami. World Journal of Gastroenterology Aug. 2004; 10(15): 2218-2222.

“Liver Transplant for HCC: A Treatment For Selected Few” Linda Wong, Naoky Tsai, Whitney Limm, Livingston Wong. Clinical Transplantation April 2004: 18(2); pp. 205-210.

"Fatal Hepatorenal Failure Associated with Hydrazine Sulfate" Mark I. Hainer, Naoky Tsai, M.D, Steven Komura, M.D., Charles L. Chiu, Pharm. D. Annal of Internal Medicine Vol.133; No.11, December 5 2000 P.877-880.

“Autoimmune features of chronic hepatitis C – experience in Hawaii” Naoky Tsai, Miles Chen, Angie Coste. In “Autoimmune Liver Disease-Its Recent Advances” Ed. By Mikio Nishioka, Seishiro Watanabe, Keiji Arima. Excerpta Medica International Congress Series 1213 ELSEVIER pp.23-29, October 2000

“Multicenter Randomized Trial of 15 Mcg Infergen Advertised Daily vs. Thrice Weekly in Patients with Chronic Hep. C Who Did Not Respond to Interferon Therapy” Tse-Ling Fong, et al. Abstract accepted and published in Hepatology Dallas, Texas. October 2000, abstract no. 759, vol. 32(4). Part 2 of 2

“Liver Transplantation in Hawaii: The initial five years” Wong, Linda M.D., Cheung, Alan H.S. M.D., Limm, Whitney M. M.D., Tsai, Naoky M.D., Shimoda, Neal M.D., Goad, Kimberly RN, Hawaii Medical Journal, Vol. 58,No. 4, April 1999, p 90-92.

"A Novel Treatment of Patients with Chronic Hepatitis C" Naoky Tsai, Neil Shimoda, Linda Wong, Stanley Shimoda, Kimberly Goad, Herbert Yee, Miles Chen Hawaii Medical Journal Vol. 58,No. 4, April 1999,p85-88

“A Pilot Randomized, Controlled Trial of the Effect of Iron-Depletion on Long-Term Response to Alpha- Interferon in Patients with Chronic Hepatitis C” Tse-Ling Fong, MD, Steven H. Han, MD, Naoky C. Tsai, MD, Timothy R. Morgan, MD, Masashi Mizokami, MD, PhD, Dajun Qian, MS, Charles Phan, MD, Kimberly Goad, RN, Allan G. Redeker, MD. Journal of Hepatology, March, 1998, 28:369- 374.

“The Effect of Iron Depletion on Long-Term Response to Alpha-Interferon in Patients with Chronic Hepatitis C Who Previously Did Not Respond to Interferon Therapy” Naoky Tsai, MD, Eli

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 10 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Zuckerman, MD, Steven H. Han, MD, Kimberly Goad, RN, Allan G. Redeker, MD, Tse-Ling Fong, MD. American Journal of Gastroenterology, Vol. 92, No. 10, Oct. 1997, pp. 1831-1834

“Incidental Schistosomiasis Found at Liver Transplantation”, Surgical Forum, Aug. 1996, Wong, L. L., Limm, Whitney M. L., Cheung, Alan H. S., Tsai, Naoky C. S.

“Transjugular Intrahepatic Portosystemeic Shunt (TIPS): Treatment of Esophageal Variceal Bleeding" Hawaii Medical Journal, Vol. 54, #1, January 1995, pp. 382-385. Lau, L. D., Wong, L. L., Tsai, N. C., Kon, K. N., Wong, L. M.

“Liver Transplantation – Hawaii Experience” Vol. 53, No. 3, March 1994 Hawaii Medical Journal, pp. 86-89, Wong, L. L., Cheung, A. H., Limm, W. M., Tsai, N. C.

“Hepatitis C – an Overview”, Hawaii Medical Journal, Vol. 50, No. 7, July 1991, pp. 229-231, N.C.

“Gastrointestinal Problems in the Elderly” Naoky Tsai, Milton Weiser, Primary Care W.B. Saunders Vol. 9 No. 1, March 1982, pp. 33-44

“Acute Pancreatitis”, Part I and Part II, Update in GI Liver Diseases, GI Division, State University of New York at Buffalo, New York, March 1981

PROTOCOLS

MERCK & CO. MK-3682-041: A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection (MK 3682-041)

GENFIT PHARMACEUTICALS GFT505-315: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

SHIRE PHARMACEUTICALS SHP626-201: A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

ROCHE MOLECULAR SYSTEMS, INC.COL-HCV-343 Collection of Blood Specimens from Subjects Infected with Chronic Hepatitis C Treated with Regimens Containing Sofosbuvir

INTERCEPT PHARMACEUTICALS 747-209: A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects with Nonalcoholic Steatohepatitis (NASH)

INTERCEPT PHARMACEUTICALS 747-303: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

GILEAD SCIENCES GS-US-283-1062: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment

GILEAD SCIENCES GS-US-330-1508: A Long Term Follow-up Registry of Subjects Treated in a Gilead- Sponsored Trial in Subjects with Chronic Hepatitis B Infection

GILEAD SCIENCES GS-US-248-0122: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 11 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017

GILEAD SCIENCES GS-US-367-1169: A Phase 2, Global, Multi-Center, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection.

GILEAD SCIENCES GS-US-330-1401: A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not in treatment.

GILEAD SCIENCES GS-US-283-1059: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally- Suppressed Subjects with Chronic Hepatitis B.

Drug Induced Liver Injury in the Setting of Dietary Supplement Use – Co-Investigator.

BRISTOL MYERS-SQUIBB AI452-016: A Long-Term Follow-Up Study of Subjects Who Participated in A Clinical Trial in Which BMS-914143 Was Administered for the Treatment of Chronic Hepatitis C (Phase 4)

ABBVIE M14-002 (PEARL-IV): A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (HCV) Infection (PEARL-IV) (Phase 3)

BRISTOL MYERS-SQUIBB AI452-017 (PRINCIPAL): A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects.

ABBVIE M13-393 (PEARL-I): A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (phase 2)

ROCHE NP28266 (ANNAPURNA): A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus ® with or without Mericitabine in HCV Genotype 1-Infected Patients Who are Either Treatment Naïve or have Previously Experienced a Null Response to Interferon-based Treatment. (Phase 2b)

NIDDK/HEPATITIS B RESEARCH NETWORK: Combination Therapy of Peginterferon Alfa-2a and Tenofovir versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B

NIDDK/HEPATITIS B RESEARCH NETWORK: Combination Entecavir and Peginterferon alfa-2a Therapy in HBeAg-Positive Immune Tolerant Adults with Chronic Hepatitis B

NIDDK/HEPATITIS B RESEARCH NETWORK: Observational Study of Persons with Hepatitis B Virus Infection in North America (Cohort Study)

JANSSEN IRELAND R&D TMC435-HPC-3001: A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy.

BECKMAN-COULTER HCV-011-01: Multi-center, Prospective Evaluation of the Beckman Coulter DxN HCV Viral Load Assay as an aid in the Management of HCV-Infected Individuals Undergoing Antiviral Therapy

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 12 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 VERTEX VX11-950-114: A phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naïve and Prior Relapser Subjects with Genotype 1 Chronic Hepatitis C and IL28B CC Genotype.

Roche PP25213: INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) with or without Copegus® in Interferon Naïve HCV Genotype 1 Infected Patients

Roche NV22776: A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus Pegasys® and Copegus® alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection

Roche NV22621: A Randomized, Double-blinded, Multicenter Study to Evaluate the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® for 24 weeks versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection

Three Rivers Pharmaceuticals: Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon alfacon-1) in Patients Chronically Infected with Hepatitis C Virus

Glaxo Smith-Kline TPL108392 (ENABLE-ALL): An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin) ENABLE-ALL (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C Related Liver DiseasE - All Subjects Withdrawing From ENABLE 1 and 2 through Lack of Response)

Bayer 12917: A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

GIDEON NX0802: Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNnib

Glaxo Smith-Kline TPL108390 (ENABLE-2): Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin) ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C Related Liver DiseasE)

Glaxo Smith-Kline TPL103922 (ENABLE-1): Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin) ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)

“Hepatitis B Virus Infection in Hawaii”: A retrospective study to evaluate the prevalence and risk of HBV among participants of a comprehensive screening program in Hawaii

Roche NV18210: Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 g Induction Dosing of Pegasys® in Combination with Higher Copegus® Doses in Treatment–naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85kg.

GlobeImmune GI-5005-01: A Phase I Double-Blind, Placebo Controlled, Dose-Escalation, Multi-Center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005-01; an Inactivated Recombinant

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 13 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Saccharomyes cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients with Chronic Hepatitis C Infection.

Roche NV15908D: An Extension Protocol to Evaluate the Long-Term Effects of Treatment with Peginterferon alfa-2a (PEG-IFN) or Interferon (IFN)-Based Tehrapisies for Patients with Chrnoic Hepatitis C.

GlaxoSmithKline FBX 104114: A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI1262570 in Chronic Hepatitis C Subjects with P\Hepatitic Fibrosis who have Failed Prior Antiviral Therapy.

Gilead GS-US-174-0103: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HbeAg Positvie Chronic Hepatitis B.

Gilead GS-US-174-0102: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B.

Roche NV17590: An Open-Label Multicenter Protocol Providing Pegylated Interferon Alfa-2a (PEGASYS) as Monotherapy or in combination with Ribavirin (COPEGUS) for Patients with Chronic Hepatitis C who have Participated in Previous Roche Protocols.

Idenix NV-02B-022: An Open-Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies.

Bristol-Myers Squibb AI463-079: Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naïve Adults with Chronic Hepatitis B Infection

Roche NV17318: Randomized, Multicenter, Double-blind, Phase IV Pilot Study Evaluating the Effect of PEGASYS doses of 180 g or 270 g in Combination with Copegus doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interferon naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Body Weight Greater than 85 kg.

Roche NV17317: Randomized, Multicenter, Open Label, Phase IV Study Evaluating the Efficacy and Safety of 16-Week Versus 24-Week Treatment with PEGASYS® in Combination with Copegus® in Interferon-naïve Patients with Chronic Hepatitis C Genotype 2 or 3 Virus Infection.

Roche WV16866: An extension, observational protocol to evaluate the long term effects of treatment with peginterferon alfa-2a (PEG-IFN) alone or in combination with lamivudine or with lamivudine alone for patients with HBeAg positive or HBeAg negative/anti-HBe positive chronic hepatitis B in the original studies WV16240 and WV16241, respectively.

Bristol-Myers Squibb AI463-900: Entecavir for Subjects with Chronic Hepatitis B Infection: An EarlyAccess Program.

Bristol-Myers Squibb AI463-901: A Preliminary Assessment of Safety and Antiviral Activity of Open- Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic Hepatitis B Who Have Viremia on Monotherapy in Other Entecavir Trials.

Bristol-Myers Squibb AI463-049: Long-Term Assessment of Treatment Outcomes with Entecavir and Lamivudine for Chronic Hepatitis B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials.

Bristol-Myers Squibb AI463-048: Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected with Hepatitis B Virus and Evidence of Hepatic Decompensation.

IDENIX NV-02B-007: A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine In Adults with Compensated Chronic Hepatitis B.

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 14 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 GAIN Trial: Does Induction PEG-Intron In Combination With Rebetol Enhance The Sustained Response Rates In Patients With Chronic Hepatitis C.

TARGET: A Comparison of the Safety and Efficacy of Two Doses of Peg-Interferon alfa-2b PEG-Intron: 1.5 mcg/kg vs. 3.0 mcg/kg) in Combination with Ribavirin (Rebetol) for Treatment of Chronic Hepatitis C Patients.

Triangle Pharmaceuticals FTCB-204: A Randomized, Double-Blind Study to Evaluate the Safety, Efficacy and Tolerability of Emtricitabine in Combination with Clevudine versus Emtricitabine Monotherapy in Patients with Chronic Hepatitis B Virus.

SPRI PO2570: PEG-Intron Maintenance Therapy vs. an Untreated Control Group for Prevention of Progression of Fibrosis in Adult Subjects With Chronic Hepatitis C With Hepatic Fibrosis (METAVIR Fibrosis Score of F2 or F3), Who Failed therapy With PEG-Intron Plus REBETOL (in Protocol No. PO2370).

SPRI PO2569: PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Interferon Plus Ribavirin.

SPRI PO2370: PEG-Intron Plus REBETOL for the treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Interferon Treatment in Combination With Ribavirin).

Bristol Myers-Squibb AI463-027: A phase III study of the safety and antiviral activity of Entecavir vs Lamivudine in adults with chronic hepatitis B infection who are negative for hepatitis B E antigen.

Bristol Myers-Squibb AI463-026: A phase III study of the comparison of Entecavir to Lamivudine in chronic hepatitis B subjects with incomplete response to current lamivudine therapy.

Bristol Myers-Squibb AI463-022: A phase III study of the safety and antiviral activity of Entecavir vs Lamivudine in adults with chronic hepatitis B infection who are positive for hepatitis B E antigen.

Roche WV16240: A Phase III partially double-blinded study evaluating the efficacy and safety of 40 kD branched pegylated interferon alfa-2a (PEG-IFN, Ro 25-8310) combined with placebo or lamivudine in HBeAg positive patients with chronic hepatitis B

WIN-R TRIAL: Comparison of PEG Interferon alfa-2b plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects.

TRI-STAR Study: A Randomized Multicenter trial of PEG-Interferon alfa 2b plus Ribavirin + / - Amantadine in Patients With Chronic Hepatitis C.

Triangle Pharmaceuticals FTCB-301: A Double-Blind, Placebo-Controlled Evaluation of Emtricitabine Once-Daily for the Treatment of Chronic Hepatitis B Virus Infection

Nr 15994: A randomized, open labeled, multicenter, efficacy and safety study of Pegasys™ plus ribavirin, Pegasys™ plus CellCept®, Pegasys™ plus amantadine, or Pegasys™ plus amantadine plus ribavirin in patients with chronic HCV infection who have not responded to at least twelve weeks of treatment with Rebetron™

IntronA + Ribavirin for Treatment of Patients with Interferon-Relapsed Chronic Hepatitis C. Sub- investigator with Robert Carithers at University of Washington.

IntronA + Ribavirin for Treatment of Patients with Chronic Hepatitis C Not Previously Treated with Interferon. Sub-investigator with Robert Carithers at University of Washington.

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 15 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 R96-419: IntronA + Ribavirin for Treatment of Patients with Interferon-Refractory or Interferon- Relapsed Chronic Hepatitis C.

NV15496: A Phase III Open-Label, Randomized, Multicenter, Parallel Dose Efficacy and Safety Study Comparing Pegylated-Interferon -2a (Ro 25-8310) to a Standard Regimen of Roferon-A in the Treatment of Patients with Chronic Hepatitis C.

NUCA 3017: A Study of Extended Lamivudine Treatment for Hepatitis B Patients Previously Enrolled in Phase II or Phase III Lamivudine Trials

The Prevalence of Hepatitis G in Chronic Heomodialysis Patients.

NUCA 3011: A Placebo Controlled Study of Lamivudine and Intron-A in Patients with Chronic Hepatitis B Infection who are Interferon Non-Responders.

The Effects of Iron Depletion Therapy in Patients with Chronic Hepatitis C Virus Infection Who Failed to Respond to Intron-A Therapy. Submitted for pulication in the American Journal of Gastroenterology.

The Effects of Iron Depletion on the Response to Intron-A Therapy in Patients with Chronic Hepatitis C Virus Infection.

Treatment of Chronic Hepatitis C With Escalating Doses of Interferon Alpha-2b and Tapering After Complete Response.

Treatment of Patients with Chronic Hepatitis C Who Failed Interferon Alpha 2b Treatment with GM- CSF (granulocyte macrophage-colony stimulating factor) – A Pilot Study.

ABSTRACTS ACCEPTED FOR POSTER PRESENTATION

Pearl-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated With Dasabuvir Plus Ombitasvir/ABT-450/r/ With or Without Ribavirin David Bernstein, Van Luo, Jacob Lalezari, David Wyles, William King, Naoky Tsai, Mitchell Davis, Thomas Sepe, Jeffrey Fessel, Martin King, Thomas Podsadecki, Curtis Cooper. Poster presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease, November 7-11, 2014, Boston, MA.

Safety of ABT-450/Ritonavir/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients Michael Fried, Adrian M Di Bisceglie, John Vierling, Edward Gane, Frederik Nevens, Simone I Strasser, Ola Weiland, Sorin Rugina, Sandra Lovell, Barbara Da Silva-Tillmann, Nancy Shulman, Naoky Tsai, David R Nelson. Poster presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease, November 7-11, 2014, Boston, MA.

Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated with ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribaivirn John Vierling, Massimo Puoti, David Bernstein, Naoky Tsai, Ola Weiland, Manuel Rombero Gomez, Florin Alexandru Caruntu, Jean-Francois DuFour, Filipe Calina, Lois Larsen, Fernando Tatsch, Pietro Andreone. Poster presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease, November 7-11, 2014, Boston, MA.

A Real Life Experience with the COSMOS Regimen in Genotype 1 Chronic Hepatitis C Treatment: Including Patients with East Asian Ancestry and Decompensated Cirrhosis.

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 16 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Marina Roytman, Resham Ramkissoon, Leena Hong, Ruby Trujillo, Leslie Huddleston, Peter Poerzgen, Todd Seto, Naoky Tsai. Poster presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease, November 7-11, 2014, Boston, MA.

Can a Dietary Supplement Induce Autoimmune Hepatitis? Marina Roytman, Peter Poerzgen, Christine L. S. Lee, Leslie Huddleston, Peter Bryant-Greenwood, Linda Wong, Naoky Tsai. Poster presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease, November 7-11, 2014, Boston, MA.

A Real Life Experience with sofosbuvir-based regimens in a community setting. Christina Wu, Marina Roytman, Leena K. Hong, Leslie Huddleston, Ruby Trujillo, Alvin Cheung, Peter Poerzgen, Naoky Tsai. Poster presented at the 65th Annual Meeting of the American Association for the Study of Liver Disease, November 7-11, 2014, Boston, MA.

Autoimmune Hepatitis in Hawaii Tanner Kim, Jaclyn Kagiharra, Naoky Tsai, Marina Roytman. Poster presented at the annual meeting of the DDW in Chicago, IL, May 6, 2014.

Cluster of severe hepatotoxicity related to the new formulation of OxyElit Pro Marina Roytman, Peter Poerzgen, Christine L. Lee, Leslie Huddleston, Timothy Kuo, Peter Bryant- Greenwood, Linda L. Wong, Naoky Tsai Presented at Late-Breaker Session, ASSLD meeting in Washington, DC, November 3, 2013.

Trial and Error: Investigational Drug Induced Liver Injury. Case Series. Ashley Murumoto, Marina M. Roytman, MD, Naoky CS Tsai, MD Presented to The American College of Physicians, Hawaii Chapter annual meeting, January 2013.

New Triple Therapy for Chronic Hepatitis C: Real Life Clinical Experience in a Community Setting. Joy Piotrowski, Matt Akiyama, Marina Roytman, Alain Chan, Leena Hong, Leslie Huddleston, Ruby Trujillo, Naoky Tsai Presented to The American College of Physicians, Hawaii Chapter, January 2013.

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis in the United States Abstract # PP09-100 APASL 2012 Taipei Taiwan Timothy Juday1, Naoky Tsai2, Lennox Jeffers3, Hong Tang4, Lael Cragin5, Sonja Sorensen6, Wayne Su7, Lisa C. Rosenblatt8, Tony Hebden9 1 Bristol-Myers Squibb; 2 John A. Burns School of Medicine, University of Hawaii at Manoa; 3 Miami VA Medical Center; 4 Bristol-Myers Squibb; 5 United BioSource; 6 United BioSource; 7 United BioSource; 8 Bristol-Myers Squibb; 9 Bristol-Myers Squibb

Five years of treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis Abstract # PS-06-05 ( Oral Presentation) 2012 APASL Edward Gane1, Naoky Tsai2, Frank Weilert3, Maria Buti4, Ira Jacobson5, Mary Kay, Washington6, Neby Bekele7, Jeffrey Bornstein8, John Flaherty9, Patrick Marcellin10 1Auckland City Hospital, 2University of Hawaii at Manoa, Honolulu, HI, 3Waikato Hospital, Hamilton, 4Hospital General Universitari Vall d’Hebron and Ciberehd, Barcelona, Spain, 5Weill-Cornell Medical College, New York, NY, 6Vanderbilt University, Nashville, TN, 7Gilead Sciences, Foster City, CA, 8Gilead Sciences, Foster City, CA, 9Gilead Sciences, Foster City, CA, 10Hopital Beaujon, Clichy

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 17 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Five years of treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis Abstract # PP09-025 APASL 2012 Naoky Tsai1, Edward Gane2, Frank Weilert3, Maria Buti4, Ira Jacobson5, Mary Kay Washington6, Neby Bekele7, Jeffrey Bornstein8, John Flaherty9, Patrick Marcellin10 1University of Hawaii at Manoa; 2Auckland City Hospital, Auckland; 3Waikato Hospital, Hamilton; 4Hospital General Universitari Vll d’Hebron and Ciberehd, Barcelona; 5Weill-Cornell Medical College, New York, NY; 6Vanderbilt University, Nashville, TN; 7Gilead Sciences, Foster City, CA; 8Gilead Sciences, Foster City, CA; 9Gilead Sciences, Foster City, CA; 10Hopital Beaujon, Clichy

Five years of treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) infection in lamivudine-experienced patients is associated with sustained viral suppression and histological improvement Naoky Tsai1, Edward Gane2, Frank Weilert3, Maria Buti4, Ira Jacobson5, Mary Kay Washington6, Nebiyou Bekele7, Kathryn Kitrinos8, John Flaherty9, Patrick Marcellin10 Abstract # PP09-008 APASL 2012 1University of Hawaii at Manoa; 2Auckland City Hospital, Auckland; 3Waikato Hospital, Hamilton; 4Hospital General Universitari Vall d’Hebron and Ciberehd, Barcelona; 5Weill-Cornell Medical College, New York, NY; 6Vanderbilt University, Nashville, TN; 7Gilead Sciences, Foster City, CA; 8Gilead Sciences, Foster City, CA; 9Gilead Sciences, Foster City, CA; 10Hopital Beaujon, Clichy

COST-EFFECTIVENESS OF ENTECAVIR VERSUS ADEFOVIR FOR THE TREATMENT OF CHRONIC HEPATITIS B IN PATIENTS WITH DECOMPENSATED CIRRHOSIS Abstract #478 AASLD 2011 Naoky Tsai2, Lennox Jeffers3, Lael Cragin4, Sonja Sorensen4, Wayne Su4, Lisa C. Rosenblatt1, Hong Tang1, Tony Hebden1, Timothy Juday1; 1Health Services, Bristol-Myers Squibb, Plainsboro, NJ; 2John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI; 3Miami VA Medical Center, Miami, FL; 4United BioSource, Lexington, MA Abstract #478 AASLD 2011

PROGNOSTIC BIOMARKER DISCOVERY IN FORMALINFIXED, PARAFFIN-EMBEDDED (FFPE) TISSUE SAMPLES OF THE LIVER Abstract # 915 AASLD 2011 Gordon S. Okimoto1, Brenda Y. Hernandez1, Michael Loomis1, Sandi Kwee1,2, Naoky Tsai1, Owen Chan1, Linda L. Wong1; 1UH Cancer Center, Honolulu, HI; 2Queen’s Medical Center, Honolulu, HI

PILOT STUDY OF INVESTIGATIONAL FLUORINE-18 FLUOROCHOLINE PET/CT FOR IMAGING OF HEPATOCELLULAR CARCINOMA IN CHRONIC LIVER DISEASE Abstract # 1123 AASLD 2011 Sandi Kwee1,2, Gordon S. Okimoto1, Naoky Tsai1, Linda L. Wong1; 1University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI; 2Hamamatsu/Queen’s PET Imaging Center, The Queen’s Medical Center, Honolulu, H

HEPATOCELLULAR CANCER IN DIFFERENT ETHNICITIES IN HAWAII: A POPULATION BASED ANALYSIS Abstract #2151 AASLD 2011 Brenda Y. Hernandez1, Lynne R. Wilkens1, Gordon S. Okimoto1,

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 18 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Sandi Kwee2,1, Owen Chan3, Naoky Tsai1, Cheryl L. Albright1, Linda L. Wong1; 1Cancer Center, University of Hawaii, Honolulu, HI; 2Nuclear Medicine, Queens Medical Center, Honolulu, HI; 3Pathology, Hawaii Medical Center East, Honolulu, HI

“Chronic Hepatitis B- Perspective in Hawaii” Oral presentation ACP/ASIM Annual Conference Jan. 2011 Hawaii D. Magliulo, Naoky Tsai, David Naai

“ Long Term (4 Yrear Efficacy and Safety of Tenofovir(TDF) Treatment in HBeAg(+) CHB (study 103)- Preliminary Analysis” E. Heathcote et al …Naoky Tsai …. Abstract #477 AASLD Boston 2010

“Long Term Entecavir Treatment for up to 5 years in Asian HBeAg(+) Nucleos(t)ide Naïve CHB Results from ETZ-022 and -901 C Pan et al ..Naoky Tsai Abstract # 478 AASLD Boston 2010

“ Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asian with HbeAg(+) CHB: Results from Study ETV-022/027” R. Gish et al …Naoky Tsai Abstract #485 AASLD Boston 2010

“ Pathway Analysis of Genome Wide Expression data from Formalin-Fixed,Paraffin-Embedded (FFPE) samples of Early-Satge HCC and Adjustant Normal Tissue” G. Okimoto et al …Naoky Tsai Abstract 533 AASLD Boston 2010

“ Treatment Outcomes and Reasons for non-treatment of CHC in a Community-Based Referral Clinic” T. Sharma …Naoky Tsai et al Abstract #990 AASLD Boston 2010

“ Racial Disparity in Pacific Islanders with HCC in Hawaii” L>L.Wong, T Sharma, Naoky Tsai Abstract # 1839 AASLD Boston 2010

“ GI-5005 Therapeutic Vaccine improves deficit in Cellular Immunity in IL28B Genotype T/T Treatment Naïve Patients with CHC G-1 When Added to SOC PEG IFN 2A /RBV” J. Vierling …Naoky Tsai et al Abstract #1973 ASSLD Boston 2010

“ GI-5005 Therapeutic Vaccine plus PEG-IFN/RBV improves SVR Vs SOC in Prior NR with G-1 CHC infection” P. Packros ….Naoky Tsai..et al LB-6 Oral Presentation AASLD Boston 2010

“GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Significantly Improves Virologic Response and ALT Normalization at the End-Of-Treatment and Improves SVR24 compared to PEG-IFN/Ribavirin in Genotype -1 Chronic Hepatitis C Patients.” IM, Jacobson, JG McHutchison, TD Boyer, ER Schiff, GT Everson, PJ Pockros, RM Chasen, JM Vierling, EJ Lawitz, M Kugelmas, NC Tsai, ML Shiffman. EASL Abstract # 2006 April 17, 2010

“ GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin inproves Biopsy Necro-Inflammatory Scores and ALT Normalization at 48weeks versus PEG-IFN/Ribavirin in Genotype -1 Chronic Hepatitis C Patients, JG McHuchison, ZD Goodman, GT Everson, IM Jacobson, TD Boyer, ER Schiff, WM Lee, RM CHasen, JM Vierling, EJ Lawitz, M Kugelmas, NC Tsai D Apelian, USA EASL Abstract # 277 April 15, 2010

“ Risk and Predictors of Mortality or HCC Among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients with Evidense of Hepatic Decompensation. YF Liaw, M Raptopoulous-Gigi, H Cheinquer, SK Sarin, T Tanwandee, N Leung, CY Peng, RP Myers, RS Brown, Jr., NC Tsai, J Bialkowska, S. Tang, E Cooney. EASL Abstract #1011, April 17, 2010

“ Risk and Predictors of Mortality or Hepatocellular Carcinoma Among Entecavir- or –Adfefovir-Treated Chronic Hepatitis B Patients With Evidence of Hepatic Decompensation Naoky Tsai, Yun-Fan Liaw, et al. Abstract # M1897 AASLD/DDW May 3 2010 New Orleans

“Low Rates of Nucleos(t)ide-Associated Adversed Events in the Long Term Experience with Entecavir” Alber t Min, Naoky Tsai,Michael Manns et al Abstract #M1901 AASLD/DDW May 3 2010 New Orleans

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 19 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 “ Patients with NASH are referred for Liver Transplant with worse renal function: Impact for MELD Score” Chan W. Park, Naoky Tsai, Linda Wong Abstract #614 Boston 60th AASLD October 30 2009

“ Successful Linkage to Care following screening for hepatitis B virus infection in the Hepblink Program.”W.Ray Kim, Karen Kim, Robert Tarrell, Denton Chase, Ke Quin Hu, Naoky C S Tsai.Abstract #714 60th AASLD Boston October 30 2009

“ GI5005 Therapeutic Vaccine plus PEG-IFN/Ribavirin improves End of Treatment response at 48 weeks VS PEG-IFN/ Ribavirin in Naïve Genotype 1 Chronic Hepatitis C Patients” John McHutchison,Ira Jacobson, Thomas Boyer, Eugene Schiff, Gregory T. Everson, William Lee, Paul Packros, Richard Chasen, John Vierling, Eric Lawitz, Marcelo Kugelmas, Naoky Tsai, Brian Armstrong, Tim Rodell, David Apelian. Abstract # LB15, 60th AASLD Boston, October 30 2009

“Effectiveness of Pre-immunization Screening for Hepatitis B Infections among Asian and Pacific Islanders (API) in Hawaii” Augustina Manuzak1,3, Naoky Tsai2,3, Aldrich Ricalde3 1Walden University, PhD in Epidemiology Candidate 2Department of Medicine, University of Hawaii John A. Burns of School of Medicine, Honolulu, HI; 3Hawaii “3 for Life” Project, Honolulu, HI American Public Health Association 136th Annual Meeting and Expo San Diego, CA Oct 25-29, 2008 POSTER # 184742

“Does Free Vaccination Lead to Higher Coverage Among Asian American Adults? Results of a Community Outreach Program Naoky Tsai ,Peter Holck, Aldrich Ricalde DDW May 2008 San Diego M1918 A-810

“ Tenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) P Marcellin, Hospital Beaujon, University of Paris, Clichy France; I Jacobson, Weill Medical College of Cornell University, New York, NY, USA; N Tsai, Hawaii Medical Center East,Honolulu, HI; N Bzowej, California Pacific Medical Center, San Francisco, CA; F Habersetzer, Hopital Civil de Strasbourg, Strasbourg France; H Senturk, Istanbul Universitesi Cerrahpassa Tip Fakultesi Hastanesi Ic Hastaliklari A.B.D. Istanbul, Turkey; C Moyes, The Hepatitis Foundation of New Zealand, Whakatane, New Zealand; G Teuber, Johann-Wolfgang Goethe Universitaet Frankfurt, Frankfurt Germany; J Sorbel, J Anderson, E Mondou, J Quinn, F Rousseau, Gilead Sciences, Durham NC USA DDW May 2008 San Diego M1908 A-808

“Cholangiocarcinoma in Asian-Americans”, C. Hammill, J. Concepcion, L. Wong, and Naoky Tsai Hepatology International: Official Journal of the Asian Pacific Association for the Study of the Liver, March 2008, V.2 No. 1, p. 110; poster presentation, Presidential Select Award, March 2008, Seoul, Korea.

“96 Weeks of Entecavir (ETV) Re-Treatment of HbeAg (-) ETV Patients Who Previously Discontinued Treatment”, C.L. Lai, T.T. Chang, T. Tanwandee, Y.C. Chao, H. Cheinquer, S.S. Wu, C. Yurdayin, M. Manns, W. Sievert, N. Tsai, H. Zhang, R. Tamez, and R. Hindes, Hepatology International: Official Journal of the Asian Pacific Association for the Study of the Liver, March 2008, V.2 No. 1, p. 110; oral presentation, March 2008, Seoul, Korea.

“Hepatocellular Carcinoma in Filipino-Americans in Hawaii”, Linda L. Wong, M.D., and Naoky Tsai, M.D., Hepatology International: Official Journal of the Asian Pacific Association for the Study of the Liver, March 2007, V. 1, No. 1, p. 56; oral presentation, March 2007, Kyoto, Japan.

“Hepatitis B Prevalence in Hawaii: Do Demographic Differences Exist?”, Naoky Tsai, M.D., Aldrich Ricalde, B.S., 2007 Hawaii Chapter Scientific Meeting of the American College of Physicians, March 3, 2007 (oral presentation), Honolulu, Hawaii

Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy: Perrillo RP, Gish RG, Peters M, Keeffe EB, Alberti A, Buti M, Cooksley GE, Fried MW, Hadziyannis SJ, Liaw YF, Naoumov NV, Schiff

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 20 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 ER, Thio CL, Tsai N, Schalm S.Abstract #218 p.92A Oral Presentation, Hot Topics in Hepatology Parallel Session 32, Nov.15, 2005 AASLD San Francisco

Health Related Quality of Life Changes After Entecavir(etv) or Lamivudine (LDV) Treatment in Lamivudine Refractory Chronic Hepatitis B (CHB) Patients- BMS study 026 Jun Su, Lisa Chen, Uchema H. Iloeje, Anne P. Cross, Robert G. Hindes, Richard B. Wilber, Jeffery A. Johnson, Steven-Huy B. Han, Naoky C. Tsai, Robert G. Gish, Morris Sherman Poster #937 DDW Chicago May 2005

Entecavir is Effective Irrespective of Baseline ALT and HBV DNA Strata for Histological and Virological Endpoints. Poster Anna Lok, Eugene Schiff, Naoky Tsai,et al DDW May 2005 Chicago Abstrcat # M934

Alanine Aminotransferase (ALT) Flares Are Less Frequent With Entecavir Than Lamivudine Treatment Both On-and Off-Treatment in HBeAg(+) patients. Naoky Tsai, M. Sherman, Steve Han et al Poster of Distinction DDW Chicago May 2005 Abstract # M942

Histologic Superiority of Entecavir to Continued Lamivudine for the Treatment of Lamivudine-Refractory Chronic Hepatitis B Infection YF Liaw, N. Tsai, S. Hadziyannis, H. Sette, Jr., Z. Goodman, A. Cross, L. Chen, K. Klesczewski, R. Hindes, D. DeHertogh, The BEHOLD Study Group. Therapies for Viral Hepatitis Workshop 2004 Poster #41. October 2004 Boston, MA.

Hepatitis B, Alcohol, but not Ethnicity Affect Survival in Hepatocellular Carcinoma. Linda Wong, Naoky Tsai, Richard Severino, Whitney Limm. NIH Hepatocellular Carcinoma Conference Poster #14, April 1-3, 2004 Washington, DC.

Triple Therapy Compared To Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin For Previous Nonresponders And Relapsers With Chronic Hepatitis C. Eric J Lawitz, Norma S Cantu, Brooke Army Medical Center, San Antonio, TX; Mitchell Davis, South Florida Center of Gastroenterology, West Palm Beach, FL; Nezam Afdhal, Michael Curry, Beth Israel Deaconess Medical Center, Boston, MA; Mark Mailliard, University of Nebraska Medical Center, Omaha, NE; Frank Adams, Austin Consultants in Gastroenterology, Austin, TX; Naoky Tsai, St. Francis Medical Center, Honolulu, HI; Andrei Gasic, Longview Gastroenterology Clinic, Longview, TX; Tarun Kothari, Private Practice, Rochester, NY; KP Ganeshappa, Digestive Disease Center of South Texas, San Antonio, TX; James Cox, Texas Digestive Disease Consultants, Lewisville, TX; Bruce Silverman, Gastroenterology Associates, Olympia, WA; Shailesh C Kadakia, Institute of Liver And Gastrointestinal Diseases, San Antonio, TX. AASLD Abstract # 1209 AASLD October 2003, Boston, MA.

Serious Ophthalmologic Events During Pegylated Interferon and Ribavirin Therapy For Chronic Hepatitis C: Observations From the WIN-R Trial. Furqaan Ahmed, Ira M Jacobson, Weill Medical College of Cornell University, New York, NY; Steve T Chen, Lancaster Gastroenterology, Lancaster, PA; Simon Cofrancesco, Gastroenterology Associates, McComb, MS; Jeffrey Cooley, Caritas-St. Elizabeth’s Medical Center, Brighton, MA; Michael Demicco, Associated Gastroenterology Medical Group, Anaheim, CA; Bradley Freilich, Baptist Medical Center, Kansas City, MO; Brian Hudes, Advanced Gastroenterology Associates, Duluth, GA; Jonathan Jensen, Front Range Gastroenterology, Longmont, CO; Arnold Levin, Eastside Gastroenterology Consultants, Kirkland, WA; Kip Lyche, Private Practice, Ventura, CA; Jonathan McCone, Mount Vernon Endoscopy Center, Alexandria, VA; Howard P Monsour, Liver Specialists of Texas, Houston, TX; Craig Peine, Hennepin County Medical Center, Minneapolis, MN; Neville Pimstone, University of California, Davis Medical Center, Sacramento, CA; Thomas Rosenfield, Medical Specialists at the Palm Beaches, Atlantis, FL; Robert Strauss, Northwest Georgia Gastroenterology, Marietta, GA; Kusum Stokes, Eureka Liver Center, Eureka, CA; Norah Terrault, University of California, San Francisco, San Francisco, CA; Naoky Tsai, St. Francis Medical Center, Honolulu, HI; Ronald B Wasserman, Infectious Disease Doctors Medical Group, Walnut Creek CA; Graham M Woolf, Cedars-Sinai Medical Center, Los Angeles, CA; Robert S Brown Jr, Columbia- Presbyterian Medical Center, New York, NY; Clifford Brass, Schering-Plough Research Institute, Kenilworth, NJ. AASLD Abstract # 1196 AASLD October 2003, Boston, MA.

Triple Therapy Compared To Standard Pegylated Interferon Alfa 2B + Weight Based Ribavirin For Treatment Naïve Chronic Hepatitis C [Tri-Star Trial]: Final Results. Eric J Lawitz, Norma S Cantu, Brooke

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 21 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 Army Medical Center, San Antonio, TX; Mitchell Davis, South Florida Center of Gastroenterology, West Palm Beach, FL; Nezam Afdhal, Michael Curry, Beth Israel Deaconess Medical Center, Boston, MA; Mark

Mailliard, University of Nebraska Medical Center, Omaha, NE; Frank Adams, Austin Consultants in Gastroenterology, Austin, TX; Naoky Tsai, St. Francis Medical Center, Honolulu, HI; Andrei Gasic, Longview Gastroenterology Clinic, Longview, TX; Tarun Kothari, Private Practice, Rochester, NY; KP Ganeshappa, Digestive Disease Center of South Texas, San Antonio, TX; James Cox, Texas Digestive Disease Consultants, Lewisville, TX; Bruce Silverman, Gastroenterology Associates, Olympia, WA; Shailesh C Kadakia, Institute of Liver And Gastrointestinal Diseases, San Antonio, TX. AASLD Abstract # 997 AASLD October 2003, Boston, MA.

Genotyping of the Core Promoter/Pre-core Sequences in Hepatitis B Virus Among Multi-Ethnic Carriers in Hawaii. Hawaii Chapter Scientific Meeting of the American College of Physicians-American Society of Internal Medicine March 8, 2003. Honolulu, Hawaii.

Genotyping of the Core Promoter/Pre-core Sequences in Hepatitis B Virus Among Multi-Ethnic Carriers in Hawaii. Asian Pacific Association of Study of Liver September 26, 2002. Taipei Taiwan

"Triple Therapy Compared to Standard Pegylated Interferon Alfa 2b + Weight Based Ribavirin for Treatment Naïve Patients with Chronic Hepatitis C: 24 Week Viral Clearance [Tri-Star Trial]" Eric J. Lawitz, Norma S. Cantu, Frank Adams, Mitchell Davis, Richard Sperling, Steven Fein, Alan P. Glombicki, Naoky Tsai, Andrei Gasic, Barry Sanders, Tarun Kothari, James Cox, For The Alamo Study Group, San Antonio, TX; Austin TX; West Palm Beach, FL; Pasadena, TX; Houston, TX; Honolulu, HI; Longview, TX; Lewisville, TX; Rochester, NY; Flower Mound, TX. AASLD Abstract # T1384. DDW May 2002, San Francisco, CA.

A randomized, open label, multicenter, efficacy and safety study of Pegasys plus ribavirin, Pegasys plus CellCept, Pegasys plus amantadine, or Pegasys plus amantadine plus ribavirin in patients with chronic HCV infection who have not responded to at least 12 weeks of treatment with Rebetron. AASLD November 2001, Dallas, TX.

The Prevalance rate of Positive HCV-Ab in Firefighters of the City and County of Honolulu--an Increased Risk with the Length of Service. May DDW 2001, Atlanta, GA

Ribavirin and Intron-A Combination Therapy for Chronic Hepatitis C Patients who Failed Previous Response to Prior Interferon Therapy Alpha Therapy. A PRELIMINARY REPORT AT THREE MONTHS END POINT, AASLD November 1996, Chicago, IL.

A Pilot Randomized, Controlled Trial of the Effect of Iron Depletion on Long-Term Response to Alpha Interferon in Patients With Chronic Hepatitis C Virus (Full article being submitted for publication) AASLD November 1996, Chicago, IL.

GM-CSF (Granulocyte-Monocyte Colony Stimulation Factor) Treatment of Patients with Chronic Hepatitis C Who Have Failed Alpha-2b Therapy---A Pilot Study (Full article being submitted for publication) AASLD November 1996, Chicago, IL.

HCV Genotype Distribution and the Prevalence of GBV-C/HGV Infection in Chronic Hepatitis C (CHC) Patients in Hawaii, AASLD November 1996, Chicago, IL.

GRANT PROPOSALS AWARDED

NIDDK Hepatitis B Clinical Research Network U01 DK082863-01 Awarded September 25th, 2008, Duration:11/01/2008 to 6/30/2015 PIs: Anna Lok, MD, University of Michigan, Naoky Tsai, MD, University of Hawaii.

“Ribavirin and Interferon Combination Therapy for Patients with Chronic Hepatitis C Who Failed Previous Interferon Therapy.” Ongoing Grant.

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 22 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 “A Phase III Open-Label, Randomized, Multicenter, Parallel Dose Efficacy and Safety Study Comparing Pegylated-Interferon Alpha 2a to a Standard Regimen of Roferon-A in Treatment of Patients with Chronic Hepatitis C.

“Interferon Alpha-2b and Ribavirin for Treatment of Patients with Interferon-Refractory or Interferon- Relapsed Chronic Hepatitis C.”

“Treatment and Retreatment of Chronic Hepatitis C with Interferon Alone or in Combination with Iron Depletion.” From February 1995 to Current.

“GM-CSF Treatment of Patients with Chronic Hepatitis C Who Failed Previous Interferon Therapy"”- A Pilot Study. From February 1995 to February 1996. Immunex Co. Seattle, Washington.

MAJOR LECTURES AND GRAND ROUNDS

October 3, 2009 “ Management of Anti-viral Resistance in chronic hepatitis B” Invited speaker Gastroenterology and Hepatology Symposium, University of California, Irvin

July 21, 2007, “Complementary Therapies for Liver Disease”, American Liver Foundation, Hawaii Chapter, Honolulu, Hawaii

June 14, 2007, “Chronic HBV and the Importance of Rapid and Profound Viral Load Reduction”, Idenix Pharmaceuticals, Honolulu, Hawaii

June 13, 2007, “Evolving Strategies in the Management of HCV”, Valeant Pharmaceuticals International, Honolulu, Hawaii

November 29, 2006, “Treatment Strategies for the HCV Nonresponder”, Valeant Pharmaceuticals International, Honolulu, Hawaii

November 16, 2006, “Clinical Trial Update in HCV: What’s New, What’s Around the Corner”, The Gut Club, Honolulu, Hawaii

September 9, 2006, “Abnormal Liver Tests”, Premier Liver Disease First Seminar, St. Francis Medical Center, Honolulu, Hawaii

April 1, 2006, “Diagnosis and Treatment of CHB”, Taiwanese Association of Hawaii, Honolulu, Hawaii

March 18, 2006, HCV and HBV lectures: ‘What Providers Need to Learn About Managing Chronic Hepatitis B and C” (healthcare providers) and “Liver Welness” (providers, general community), American Liver Foundation, Molokai, Hawaii

Nov. 29-December 2, 2005, UC Davis Health System CME Gastrienterology and Hepatology for GI Specialists, Hepatologists, and Primary Care Clinicians Maui Hawaii invited Speaker.

October 15, 2005, Micronesian Community Conference invited guest speaker “Significance of Chronic Hepatitis B in Micronesian Population and It’s Impact.”

October 13, 2005, St. Francis Medical Center Medica, Grand Round “Hepatitis B Update”

September 25 2005, North American Taiwanese Medical Association Annual Convention lecture “Updates on Hepatitis B” City of Industry, California

Aug. 23 2005, JABSOM Grand Round, “Wilson Disease-Acute Liver Failure”

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 23 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 June 26-27, 2004, Contribution of Taiwanese Research to the Understanding of Viral Hepatitis – A Tribute to Professor Sung Juei Low, “Practical Management of Chronic Hepatitis B in US”, Sheraton Waikiki – Honolulu, Hawaii.

April 10, 2004, Hepatitis B in the Islands, the Pacific Rim and Asian Countries at Harris United Methodist Church, “Hepatitis B in Asia, the Pacific Islands, the US mainland and Hawaii”, Honolulu, Hawaii.

April 10, 2004 Continuing Medical Education Lecture at Royal Hawaiian Hotel, “Update on Hepatitis B”, Honolulu, Hawaii.

April 4, 2004 Speaker for NATMA Meeting Washington DC/Virginia/Maryland Tri-State Combined Lecture, “Practical Management of Chronic Hepatitis B”, Washington, DC.

March 30, 2004 Speaker at the Hepatitis in the Heartland – Regional Viral Hepatitis Conference, “Controversies in Hepatitis C Therapy”, Overland Park City, Kansas.

March 1-6, 2004 Visiting Professor Lecturer “Management of Chronic Hepatitis, Liver Failure, and NASH” Hanoi, Hue, and Ho Chih Minh City, Vietnam.

October 26, 2003 Controversies in Hepatitis C Therapy Symposium - Point/Counterpoint, “Should CAM Therapies Have a Role in HCV Treatment?” AASLD 2003, Boston, MA.

August 26, 2003 Continuing Medical Education Presentation at Castle Medical Center, “Colorectal Cancer: Epidemiology, Screening and Genetic Counseling”, Kailua, Hawaii.

August 6, 2003 University of Hawaii Grand Round. “Epidemiology of Irritable Bowel Syndrome”

July 19, 2003 Invited Speaker at Treating and Managing Chronic Viral Hepatitis in Patients Living in the Pacific Rim, “HBV Management: State of the Art: Interferon vs. Oral Agents or Both?” Sonoma, CA.

April 4, 2003 Invited Colloquium Speaker at John A. Burns School of Medicine University of Hawaii “The Liver”

February 12, 2003 Speaker for AdvancMed at Halekulani Hotel, Honolulu, Hawaii, “Managing Treatment Outcomes for HCV-Related Anemia”

September 14, 2002 Invited Speaker for the 5th US-Japan Meeting on Autoimmune Liver Diseases, “Autoimmunity After Liver Transplantation”

August 24, 2002 Invited Speaker for the 11th Annual Hawaii Gastroenterology Symposium “Treatment of Hepatitis B and C “

August 13, 2002 The Queen’s Medical Center Gastroenterology Division Honolulu Gut Club Lecture Series “Update on Current Clinical Trials for Viral Hepatitis in Hawaii”

August 8, 2002 St. Francis Medical Center Medical Conference “ Acute Liver Failure in a Patient with Heart Disease”.

May 7, 2002 CME presentation Castle Medical Center “ How to Evaluate Patients with Abnormal Liver Tests”

March 20, 2002 University of Hawaii John A. Burns School of Medicine First Year Medical Student Colloquium Lecture "The Liver and Liver Disease".

February 26, 2002 University of Hawaii Grand Round. "Hepatocellular Carcinoma and Chronic Hep C".

February 1, 2002 Grand Round, SFMC-West "Abnormal LFT".

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 24 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017

December 18, 2001 Invited Guest Lecture Hawaii Pharmacist Association " Update in the treatment of Chronic Hepatitis C".

December 18, 2001 Special grand round " Acute Fulminant Liver Failure in a patient with hepatitis C " St. Francis Medical Center, Liliha.

October 9, 2001, CME lecture at Castle Medical Center " Update in diagnosis and treatment of Chronic Hepatitis C in the new millenium"

September 26-30, 2001 Visiting Professor for University of Iowa, Topics are "Update on Diagnosis and Treatment of Chronic Hepatitis B", "Non-Alcoholic Steatohepatitis", "Herbal Medicine for the Treatment of Chronic Liver Disease".

September 21, 2001 Key Note speaker for Pacific Northwest Hepatology Research Consortium sponsored by Division of Gastroenterology, Hepatology section, University of Washington-Seattle.

August 17, 2001 Invited guest lecture for East Hawaii IPA in Kona Hawaii " Progress in the treatment of Chronic Hepatitis C"

June 30, 2001 Invited special lecture to North America Taiwanese Medical Association at the annual convention in Las Vegas, "Update in Diagnosis and Treatment of Chronic Hepatitis B"

June 21, 2001 Invited guest lecture for Maui Memorial Hospital Medical Staff CME program " Progress in Treatment of Chronic Hepatitis C"

June 6, 2001 "Diagnosis and Treatment of Chronic Hepatitis B" special lecture, Family Practice Residency Program, U.H JABSOM

April 28, 2001 Medical School lecture on liver and liver disease at UH Manoa

Jan. 25, 2001 “Progress in the Treatment of Hepatitis C” Gut Club Honolulu, HI

September 29, 2000. CME Conference delivered to the medical staff at St. Francis West, Honolulu, HI “Update on Management of Chronic Hepatitis C in the New Millenium”

September 14, 2000. Special Lecture to the 4th US-Japan Autoimmune Hepatitis Society ”Autoimmunity and Chronic Hepatitis C-Facts or Fiction”

March 3, 2000, Update Family Practice Lecture: “Chronic Hepatitis C”; Hawaii Academy of Family Physicians, Honolulu, HI

October 29th, 1999, Update in the Diagnosis and Management of Liver Cirrhosis: Post-graduate course, DDW-J Hiroshima, Japan

October 31, 1999, The Third US-Japan Meeting on Autoimmune Liver Diseases, Present Article: Autoimmune Features of Chronic Hepatitis C in Hawaii, Kagawa Medical University, Hiroshima Japan

October 31, 1999, The Third US-Japan Meeting on Autoimmune Liver Diseases, Chairperson: A case of autoimmune hepatitis with high titer of AMA and normal gamma-globulinemia, Kagawa Medical University, Hiroshima Japan

October 31, 1999, The Third US-Japan Meeting on Autoimmune Liver Diseases, Chairperson: A clinicopathological study of two patients with steatohepatitis, whose clinical and laboratory features indicated “probable” autoimmune hepatitis, Kagawa Medical University, Hiroshima Japan

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 25 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 October 31, 1999, The Third US-Japan Meeting on Autoimmune Liver Diseases, Case Study Presentation: Cholestatic Liver Disease Patient with AMA (-), PDH-Ab Ig (+) and Anti-seizure Therapy, Kagawa Medical University, Hiroshima Japan

May 30, 1999, Featured speaker at the Annual Meeting and Symposium of Association of Chinese Scholars in Hawaii—“Helicobacter Pylori, Peptic Ulcer Disease, and Esophageal Cancer”

May 15, 1999, Case presentation at the Cholestatic Hepatitis Symposium in Orlando, Florida

April 30, 1999, SFMC Surgical Grand Rounds “Update on Hepatitis B”. Honolulu, Hawaii

April 20, 1999, ASPAN’s 18th National, First International Conference, “Hepatitis C: Current Diagnosis and Treatment”. Hilton Hawaiian Village, Honolulu, Hawaii

October 23, 1998, Queen’s Internal Medicine Conference, “Evolution of Therapy for Chronic Hepatitis C”. Queen’s Medical Center, Honolulu, Hawaii

September 7 & 8, 1998, Conference, Second US-Japan Association for Autoimmune Liver Disease, Commentator in Scientific Presentation, Turtle Bay Hilton, Honolulu, Hawaii

June 30, 1998, CME Conference, “Interpretation of Viral Hepatitis Serology”. Castle Medical Center, Kailua, Hawaii

June 8, 1998, Grand round, “Update of Diagnosis and Management of Chronic Hepatitis C.”, Taipei Medical College, Taipei, Taiwan

April 17, 1998, Unit 3, Medical School Lecture

March 28, 1998, Featured speaker to Formosa Physicians’ Association: Washington, D.C.

March 5, 1998, M & M Conference Speaker: “A 50-year-old Caucasian Male Attorney Presenting with Abdominal Distension”, St. Francis Medical Center

November 13, 1997, Speaker at Castle Medical Center Grand Rounds: “H. Pylori: New Developments in Diagnosis and Treatment”

November 1, 1997, Featured speaker at the HMA 141st Annual Meeting, Hilton Waikoloa Village in Kamuela, Hawaii: “The ABC of Hepatitis”

October 31, 1997, Featured speaker at the HMA 141st Annual Meeting, Hilton Waikoloa Village in Kamuela, Hawaii: “The ABC of Hepatitis”

October 30, 1997, Featured speaker at Queen’s Medical Center. Medicine Staff Conference: “Update in Diagnosis and Management of Chronic Hepatitis C”

October 15, 1997, Featured speaker at Clinical Trials Update Meeting, Cancer Research Center, UH School of Medicine: “Viral Hepatitis and Hepatocellular Carcinoma”

August 18, 1997, Grand Rounds at Pali Momi Medical Center: “Update on Management of Chronic Hepatitis C”

January 19, 1997, The First Annual Sam Booker Memorial Lecture: “Helicobacter Pylori and Ulcer Disease: Current Diagnosis and Therapies”

January 5, 1997, Half a day conference with lecture and panel discussion, Mandarin Hotel Honolulu, Hawaii, sponsored by Continuing Medical Education at St. Francis Medical Center and Chiron Laboratory and Biotechnology. Participants: Eugene Schiff, M.D., Robert Gish, M.D., Naoky Tsai, M.D.

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 26 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017 December 5, 1996, Maui Memorial Hospital Grand Round Lecture “Current Treatment of Chronic Hepatitis C”

December 1996, Grand Rounds and Visiting Professor at National Chen-Kung University and Taipei Medical College, Taiwan

November 1996, National Meeting of AASLD (American Association for Study of Liver Disease) at Chicago, three posters accepted for exhibit

October 1996, UH Grand Rounds “Chronic Hepatitis C - From Bench to Bedside”

December 1995, Grand Rounds at National Chen-Kung University, Tainan, Taiwan

November 9, 1995 Hepatitis Foundation International. Sponsored “Hepatitis A, B and C – Advances in Clinical Management

November 1995, Second US-Japan Liver Investigators Meeting, Chicago. “Iron Depletion Therapy of Treatment – Naive patient with Chronic Hepatitis C” and Panel Discussion

August 1995, Grand Rounds at Guam Memorial Hospital, Topic “Viral Hepatitis.” Sponsored by GMH and Schering-Plough Lab

March 1995, US-Japan Liver Investigators Meeting #1, Hawaii – Panel Discussions, Participants from US: Robert Carithers, MD (University of Washington), Paul Martin, MD (UCLA), David Gretch, MD (UW), Robert Gish, MD (UC-Davis), Naoky Tsai, MD (UH)

February 1995, CME Conference Sponsored by St. Francis Medical Center and Schering-Plough Lab. “Treatment of Chronic Hepatitis C”--- Lecture and Panel Discussions, Halekulani Hotel, Honolulu, Hawaii

Updated 01/15/11, 02/13/2012, 3/28/2012, 08/31/2012, 2/12/2013, 06/26/2013, 09/18/2013, 10/09/2013, 01/31/2014, 27 4/23/2015, 7/17/15, 8/4/2016, 1/10/2017, 2/8/2017